Cerevance Media Center
Solengepras Leads the Shift Beyond Dopamine
Current News
March 31, 2022
Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism
Cerevance today announced the completion of its Phase 2 clinical trial of CVN424, the company’s first-in-class, once-a-day, orally-delivered compound in development for the treatment of Parkinson’s disease.
January 25, 2022
Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766
Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766
September 8, 2021
Neuroscience Drug Development Veteran Mike Poole, M.D., FACP, to Join Cerevance Board of Directors
Cerevance today announced the appointment of Mike Poole, M.D., FACP, to Cerevance’s Board of Directors.
February 1, 2021
Cerevance Appoints Naidong Ye, Ph.D. as Vice President and Head of Chemistry, Manufacturing and Controls
Cerevance today announced the appointment of Naidong Ye, Ph.D., a seasoned chemist with extensive pharmaceutical industry experience, as vice president and head of chemistry, manufacturing and controls (CMC).
News Archive
October 7, 2026
Cerevance to Present Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson's Disease
- Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2
- Statistically significant improvements in secondary endpoints of ON time without troublesome dyskinesia and motor experiences of daily living (MDS-UPDRS Part II)
- Improvements in daytime sleepiness (Epworth Sleepiness Scale) and quality of life (PDQ-39, exploratory) point to broad motor and non-motor benefit
- Generally well tolerated, with fewer adverse events than those typically associated with dopaminergic adjunctive therapies, and a discontinuation rate similar to placebo
- Cerevance to meet with FDA to discuss the path to a potential New Drug Application
February 23, 2026
Cerevance to Participate in the TD Cowen 46th Annual Health Care Conference
December 1, 2025
Cerevance to Participate in RBC Capital Markets 2025 Healthcare Private Company Conference
November 24, 2025
Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting
Events Archive
October 30, 2026

A Binding Site for CVN293 Reveals a Mechanism for Allosteric Control of THIK-1 K2P Channel Gating
February 4, 2026

Discovery of Potent, Selective and Brain-Penetrant Small Molecule CD38 Inhibitors
October 21, 2024
CVN424, a GPR6 Inverse Agonist, for Parkinson’s Disease and Motor Fluctuations: A Double-Blind, Randomized, Phase 2 Trial
June 30, 2021




